Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | IL1B | P01584 | 12/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27182192 | 0.90 | NLRP3 (0.52) | NLRP3KCNH2IL1BCHEK1CHEK2 | |
| SCHEMBL26434531 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326492 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326421 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29975000 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL24696096 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326357 | 0.88 | NLRP3 (0.68) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326491 | 0.88 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL30684875 | 0.87 | CHEK2 (0.53) | NLRP3KCNH2IL1BCHEK1CHEK2 | |
| SCHEMBL29155947 | 0.87 | CHEK2 (0.53) | NLRP3KCNH2IL1BCHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117222626-A | Substituted triazine compounds | 安斯泰来制药株式会社 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | disclosed |